Replies to post #218114 on Anavex Life Sciences Corp (AVXL)

[Stockdoggy]

Excellent. Thanks for posting....

[makemydaze]

Thanks for that article - Michele adds nice details to what she writes and she's pretty prolific. Fans of her work can access more of what she does here:

https://www.mdedge.com/authors/michele-g-sullivan

[plexrec]

Nice posts this morning Investor---lifted my spirit a bit amidst our dismal SP performance as of late--there is still potential here---long and holding !!!!

[roygbiv]

Thanks for posting.

Things shifted dramatically in 2017, with a seminal paper finding that germ-free mice inoculated with stool from Parkinson’s patients developed Parkinson’s symptoms.

Inoculate Germ-free mice with stool from each individual patient then analyze for the most effective treatment?

[georgejjl]

VERY INTERESTING!!!

Things shifted dramatically in 2017, with a seminal paper finding that germ-free mice inoculated with stool from Parkinson’s patients developed Parkinson’s symptoms. This study was widely heralded as a breakthrough in the field—the first time any neurodegenerative disease had been conclusively linked to dysregulations in the human microbiome.

After up to 148 weeks treatment with Anavex 2-73, patients with stable or improved functional scores showed significantly higher levels of both Ruminococcaceae and Porphyromonadaceae, compared with patients who had declining function. Both bacterial families produce butyrate, an anti-inflammatory short-chain fatty acid.

Conversely, poor response was associated with a low level of Verrucomicrobia, a mucin-degrading phylum thought to be important in gut homeostasis. These bacteria live mainly in the intestinal mucosa—the physical interface between the microbiome and the rest of the body.

https://www.neurologyreviews-digital.com/neurologyreviews/nr_november_2019/MobilePagedArticle.action?articleId=1535393#articleId1535393

Good luck and GOD bless,

[BIOChecker4]

Interesting article. What struck me is how this is still an early stage science experiment with many more questions than answers. It's going to take many years and tens if not hundreds of millions of dollars to fully understand the effects of Sigma 1 upregulation on Alzheimer's disease (and other CNS diseases) and to get to an approvable drug.

AVXL is not going to be $30 or more by the end of this month, the market cap is not going to be over $30 billion by next November nor will it be over $200 billion by the end of 2020, and there will not be three approvals this year.